What Is Zyklophin? Definition and What Research Reports

Definition

Zyklophin is a synthetic cyclic peptide used in preclinical neuroscience and medicinal-chemistry research as a selective antagonist at the kappa opioid receptor (KOR). It is a chemically modified analogue of the endogenous opioid neuropeptide dynorphin A, built on the dynorphin A(1–11)amide sequence and closed into a ring (cyclised) through a side-chain-to-side-chain linkage, with an additional modification at the N-terminal tyrosine. That combination of changes converted a receptor agonist template into an antagonist template. Zyklophin was introduced as a systemically active, selective KOR peptide antagonist with a short duration of action (PMID 19841255). It has no approved therapeutic use in humans and appears in the literature strictly as a laboratory tool compound.

What Class of Molecule Is It, and Where Does It Come From?

Zyklophin belongs to the class of peptide opioid receptor ligands — specifically, the subgroup of dynorphin-derived analogues designed to block rather than activate the kappa receptor. Dynorphin A is the body's principal endogenous agonist at KOR; chemists have long used its sequence as a scaffold, replacing residues and constraining the backbone to change how the peptide engages the receptor.

Three features are usually named when the molecule is described in papers:

• Dynorphin A(1–11)amide backbone — the first eleven residues of dynorphin A, with a C-terminal amide rather than a free acid.
• Cyclisation — a covalent bridge between side chains that locks part of the peptide into a ring, which is where the "zyklo-" (cyclo) name comes from.
• N-terminal modification — a substitution at the message-region tyrosine, a change commonly associated with converting opioid agonists into antagonists.

Because it is a peptide rather than a small alkaloid, zyklophin sits apart from the classical non-peptide kappa antagonists such as norbinaltorphimine (norBNI). Peptides of this size are generally not orally absorbed, and the original report emphasised that the compound was active after systemic (non-central) administration in rodents, which was unusual for a peptide of this class (PMID 19841255).

How the Term Is Used in Peptide Research

In published work, "zyklophin" is used in a narrow, technical way: as the name of a pharmacological probe. Researchers reach for it when they want to interrupt kappa opioid signalling in an animal experiment for a limited window of time and then let the system recover. That is the practical point of difference from norBNI, whose blockade of KOR in rodents is famously long-lasting — a property that complicates repeated-measures designs because a single administration can influence behaviour for a long period afterwards.

The term therefore shows up in three kinds of paper:

1. Medicinal chemistry, where zyklophin is the parent structure for analogue series and structure–activity relationship (SAR) mapping (PMID 26491810).
2. Behavioural pharmacology, where it is compared against other kappa antagonists to ask whether the duration of receptor blockade changes the behavioural read-out (PMID 26780565).
3. Comparative and mechanistic work, where its effects are examined across different species or where unexpected responses, such as scratching, are characterised (PMID 26992699, PMID 24503508).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medicines or research involving humans.

What the Published Literature Reports

The original description

The compound was introduced in a 2009 report that characterised it as a systemically active, selective kappa opioid receptor peptide antagonist with a short duration of action, distinguishing it from the long-lasting blockade produced by earlier kappa antagonists (PMID 19841255). That short duration is the single property most often cited when later papers explain why they chose it.

Structure–activity relationships

A 2015 medicinal-chemistry study examined the structure–activity relationships of zyklophin by preparing analogues of the peptide and testing how individual structural changes affected kappa opioid receptor binding and antagonist activity, work that mapped which residues and constraints the pharmacology depended on (PMID 26491810). Studies of this kind are how a tool compound is refined — they indicate which parts of the molecule can be altered without losing selectivity.

Behavioural comparisons with long-acting antagonists

A 2016 study compared two short-acting kappa opioid receptor antagonists, zyklophin and the non-peptide LY2444296, with the long-acting antagonist norbinaltorphimine in mouse anxiety tests, and researchers reported that the short-acting compounds produced behavioural effects that differed from those of norbinaltorphimine (PMID 26780565). The study is frequently referenced as evidence that duration of kappa receptor blockade is itself a variable that can shape the behavioural outcome, rather than an incidental pharmacokinetic detail.

Species differences

A separate 2016 report examined species differences in the effects of the kappa opioid receptor antagonist zyklophin, indicating that results obtained in one rodent species did not necessarily transfer to another (PMID 26992699). For a glossary definition the practical implication is simple: descriptions of "what zyklophin does" are species- and assay-specific in the published record.

Observations in Animals: What Studies Report

Published animal findings are not safety data for humans, and no human trial of zyklophin appears in the verified literature summarised here. One finding is nonetheless routinely mentioned in reviews of the compound: a 2014 report described that zyklophin induced scratching in mice, a behavioural response the authors characterised as part of the compound's profile (PMID 24503508). Scratching in rodents is commonly used as a proxy for itch-related behaviour, and its appearance with a peptide antagonist is the kind of off-target or secondary observation that shapes how a tool compound is subsequently used in experimental design.

Beyond that, researchers have reported that behavioural effects in anxiety assays diverged from those of the long-acting antagonist norbinaltorphimine (PMID 26780565) and that effects differed across species (PMID 26992699). No dosing information is summarised on this page.

Related Terms Often Seen Alongside Zyklophin

Status and Limitations

Zyklophin is not an approved drug in any jurisdiction known to this summary, and it does not appear in the verified literature as having been tested in humans. Materials of this kind are handled as research chemicals intended for laboratory investigation only. The published evidence base is small, animal-based, and concentrated on pharmacological characterisation rather than therapeutic outcomes.

Three limitations are worth holding in mind when reading any description of the compound:

• Species dependence. Effects were reported to differ between species (PMID 26992699), so a single-species result is not a general statement.
• Duration as a confound. Short-acting and long-acting kappa antagonists produced different behavioural effects in mouse anxiety tests (PMID 26780565), meaning "kappa blockade" is not one uniform manipulation.
• Secondary behaviours. Scratching was reported in mice after zyklophin administration (PMID 24503508), a reminder that tool compounds carry their own behavioural signatures.

References

• Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action (Proceedings of the National Academy of Sciences of the United States of America, 2009)
• Zyklophin, a short-acting kappa opioid antagonist, induces scratching in mice (Neuroscience Letters, 2014)
• Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin (Journal of Medicinal Chemistry, 2015)
• Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests (Neuroscience Letters, 2016)
• Species differences in the effects of the κ-opioid receptor antagonist zyklophin (Alcohol, 2016)